gms | German Medical Science

26th Annual Meeting of the German Retina Society

German Retina Society

27.09.2013, Hamburg

Article

Send article

Evaluation of the effects of ranibizumab (Lucentis®) therapy on the macular function in patients with wet age-related macular degeneration using multifocal-electroretinogram and microperimetry

Meeting Abstract

Search Medline for

  • Mihaela Reinsberg - University of Lübeck, Department of Ophthalmology, Lübeck, Germany
  • R.-D. Hilgers - RWTH Aachen University, Department of Medical Statistics, Aachen, Germany
  • J. Lüke - University of Lübeck, Department of Ophthalmology, Lübeck, Germany
  • K. Nassar - University of Lübeck, Department of Ophthalmology, Lübeck, Germany
  • S. Grisanti - University of Lübeck, Department of Ophthalmology, Lübeck, Germany
  • I. Lüdeke - University of Lübeck, Department of Ophthalmology, Lübeck, Germany
  • M. Lüke - University of Lübeck, Department of Ophthalmology, Lübeck, Germany

Retinologische Gesellschaft. 26. Jahrestagung der Retinologischen Gesellschaft. Hamburg, 27.-27.09.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013. Doc13rg13

doi: 10.3205/13rg13, urn:nbn:de:0183-13rg138

Published: August 20, 2013

© 2013 Reinsberg et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Purpose: The purpose of this study was to evaluate the macular function under the treatment with ranibizumab (Lucentis®) in wet age-related macular degeneration (AMD) observed by multifocalelectroretinogram (ERG) and microperimetry.

Methods: Twenty subjects with neovascluar AMD meeting the inclusion criteria were assigned to ranibizumab treatment. The treatment was adapted to the Pronto-study. During a twelve months interval best corrected visual acuity (BCVA), standard ophthalmic examination, retinal thickness observed by OCT, multifocal-ERG and microperimetry has been performed monthly. The decision for reinjections has been made based on the results of patients’ examination. The study has been finished in March 2013.

Results: Descriptive statistics will be provided for patient demographics and all baseline characteristics. Relevant medical history (ocular and non-ocular) and current medical conditions as well as other relevant baseline information will be listed and summarized by appropriate descriptive statistics. Our primary interest will be to report the course of the multifocal-ERG and microperimetry measurements during the twelve months follow-up period and to analyze the relations to the clinical outcome by means of BCVA (ETDRS score) and the fovea thickness (μm).

Conclusions: This study will provide a new insight into the development of the macular function during the treatment with ranibizumab (Lucentis®) and about the significance of multifocal-electroretinogram and microperimetry in the course of wet AMD.